1) Kirsi Vaali, at present there is no affiliation with universities. 2) Kirsi Vaali attained her Master of Science in biochemistry in 1988, PhD in pharmacology and toxicology in 2001, and got her Assistant Professorship in 2010, all these educations are performed at the University of Helsinki. 3) During her research career, she has shown, in a canine model, how oral recombinant β-lactamase can degrade i.v. ampicillin intestinally and decrease antibiotic-induced adverse effects, without impact on the fecal microbiota in this model. The treatment modality proceeded to Phase II studies in humans. In 2003-2006, she published a mouse model of food allergy without immunological adjuvants. In this physiologically feasible model, light skin wounding together with oral challenge to the GI-tract developed food allergy with clinical symptoms. In 2006–2010, she was invited to an IBS research group of Prof. Arnold Berstad at Bergen University. There, she guided four PhD students in IBS, in models of food allergy and isocyanate-induced asthma. After returning back to Helsinki, she got interested in indoor air problem and inflammasome activation. Together with Assistant Prof. Tamara Tuuminen she created the concept of dampness and mold hypersensitivity syndrome (DMHS). Her proof-of-principle publication 2022 in JOF showed mycotoxin from indoor air water condensates and in the urine samples of the exposed subjects.